PFOS and Its Commercial Alternative, 6:2 Cl-PFESA, Induce Multidrug Resistance in Pancreatic Cancer
The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Abstract
Per- and polyfluoroalkyl substances (PFAS), specifically perfluorooctanesulfonate (PFOS) and its alternative, 2-[(6-chloro-1,1,2,2,3,3,4,4,5,5,6,6-dodecafluorohexyl)oxy]-1,1,2,2-tetrafluoroethanesulfonic acid (6:2 Cl-PFESA), are associated with environmental health concerns and potential cancer progression. However, their impact on multidrug resistance (MDR) in pancreatic cancer (PC) chemotherapy remains unclear. Here, we employed drug-sensitivity assays, including IC 50 calculations, in vitro and in vivo models with various chemotherapeutics, and paclitaxel (PTX) as a representative agent, combined with transcriptomic/proteomic sequencing and clinical prognostic analysis, to identify MDR-related genes and validate their relevance, with the objective of establishing the correlation between PFOS/6:2 Cl-PFESA exposure and MDR in PC at molecular, cellular, and animal model levels. Our findings demonstrate that PFOS/6:2 Cl-PFESA exposure increases the drug IC 50 in three different PC cell lines for various chemotherapeutic agents. Compared with PFOS, 6:2 Cl-PFESA demonstrated a more pro-MDR effect on PC cells in vitro . In vivo experiments further revealed that PFOS/6:2 Cl-PFESA exposures significantly reduced the efficacy of PTX in PC, with inhibition rates dropping from 78.3% to 23.8%/6.1%, respectively ( p < 0.05). This effect was driven by the aberrant activation of the PI3K-ABCB1 pathway, with 6:2 Cl-PFESA demonstrating a stronger capacity to promote this signal pathway's ex…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“HFPO oligomers and 6:2 Cl-PFESA demonstrated significantly higher accumulation factors than their predecessors, PFOA in fluorochemical production and PFOS in chrome plating, respectively42,43”
From Identification of a PFAS hyperaccumulator and elucidation of its translocation mechanism for sustainable phytoremediation (2025) · cites this paper as [43]
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Vincent, A., Herman, J., Schulick, R., Hruban, R. H., & Goggins, M. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62307-0 · Cited by 2,586
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors
Klein, A. P. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00457-x · Cited by 1,258
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
mTOR signalling and cellular metabolism are mutual determinants in cancer
Mossmann, D., Park, S., & Hall, M. N. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0074-8 · Cited by 1,088
Targeting tumor-associated macrophages to synergize tumor immunotherapy
Xiang, X., Wang, J., Lu, D., & Xu, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00484-9 · Cited by 966
Acquired Resistance to Immune Checkpoint Inhibitors
Schoenfeld, A. J., & Hellmann, M. D. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.017 · Cited by 955
Optimizing the outcomes of pancreatic cancer surgery
Strobel, O., Neoptolemos, J., Jäger, D., & Büchler, M. W. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0112-1 · Cited by 943
Challenges and Opportunities for Pancreatic Cancer Immunotherapy
Bear, A. S., Vonderheide, R. H., & O'Hara, M. H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.004 · Cited by 674
Research works printed but not linked: 1
- Hong J., 2020, Am. J. Transl. Res., 12, 551
Cited by
Guo, X., Zhang, X., Chen, J., Shan, W., Wang, R., Wang, K., Chen, Z., Wang, L., & Zhang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-65191-3 · Cited by 18
“Forexample,HFPOoligomersand 6:2 Cl-PFESA demonstrated signi fi cantly higher accumulation factors than their predecessors, PFOA in fl uorochemicalproductionand PFOS in chrome plating, respectively 42,43 (Supplementary Fig.”
Briassoulis, G., Ilia, S., & Briassouli, E. (2025) · Life · doi:10.3390/life15071057 · Cited by 15
“This systemic disruption has potential implications for multi-drug resistance (MDR): notably, 6:2 Cl-PFESA, a PFOS substitute, has been shown to influence MDR mechanisms, underlining the need for rigorous evaluations of its carcinogenic potential [114].”
Xu, D., Xiang, J., Qin, R., Chen, Z., Wang, X., Xu, P., Pan, Y., Zhang, X., Wang, Y., Cheng, P., et al. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.139882 · Cited by 5
Self-citationLiu, J., Pang, X., Li, X., Huang, N., Xu, J., Wu, Q., Yao, R., Liu, B., Lu, H., & Lian, J. (2025) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2025.140583 · Cited by 3
Jiang, J., Meng, H., Shu, Z., Zhao, N., Lin, X., Li, J., Qin, M., Wu, S., & Qiu, L. (2026) · Environmental Science & Technology · doi:10.1021/acs.est.5c11476 · Cited by 2
Metadata
- Authors
- Hong, J., Du, K., Zhang, W., Jiang, Y., Yu, H., Pan, T., Wu, T., Zhao, L., Du, W., Zheng, S.-S., Jin, H., Chen, Y., & Cao, L.
- Affiliations
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, PR China
- Chinese Research Academy of Environmental Sciences (CN)
- Kunming University of Science and Technology (CN)
- Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China
- Zhejiang University of Technology (CN)
- Corresponding author
- Jin, Hangbiao
- Chen, Yuanchen
- Cao, Linping
- ORCID
- Venue
- Environmental Science & Technology
- Publisher
- American Chemical Society (ACS)
- Published
- 2024-12-07
- Volume
- 58
- Issue
- 50
- Pages
- 22027-22038
- ISSN
- 0013-936X (ISSN-L)
- 1520-5851
- OpenAlex
- W4405130441
- Cited by
- 16
- References
- 77
- Citations by year
- 2026: 12 · 2025: 4
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Environmental Science & Technology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundamental Research Funds for the Central Universities (226-2024-00117)
- National Natural Science Foundation of China (21806139, 42177390)
- Innovative Research Groups of National Natural Science Foundation of China (81721091)
- Topics
- Physical Sciences › Environmental Science › Environmental Chemistry › Per- and polyfluoroalkyl substances research
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- PFOS, per- and polyfluoroalkyl substances, multidrug resistance, pancreatic cancer, paclitaxel, P-glycoprotein, chemotherapeutic drug resistance, PFAS alternatives, cancer risk assessment
- MeSH terms
- Animals, Fluorocarbons, Humans, Pancreatic Neoplasms, Alkanesulfonic Acids, Drug Resistance, Multiple, Drug Resistance, Neoplasm, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.